A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study is conducted to select the THR-687 dose level (Part A of the study) and to assess
the efficacy and safety of the selected dose level compared to aflibercept (Part B of the
study).